IN BRIEF: Angle Says FDA Accepts Parsotix Submission For Breast Cancer Read More
IN BRIEF: Angle Submits US FDA De Novo Application For Parsortix Read More
UK Shareholder Meetings Calendar - Next 7 Days Read More
Angle's Parsortix Able To Predict Patients' Response To Treatment Read More
IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix Read More
Angle Progresses On Parsortix And De Novo Clearance From US Regulator Read More
UK Earnings, Trading Statements Calendar - Next 7 Days Read More
IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board Read More
Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects Read More
UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE Read More
UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial Read More
Angle Parsortix Test Used To Help Discover Brain Metastasis Read More
Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients Read More
Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival Read More
Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance Read More
Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter Read More
Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma Read More
Angle Submits Positive Test Results For Parsortix System To US FDA Read More
Angle Notes Queen Mary University's European Cancer Prognosis Patent Read More
